Understanding the Potential of Antibody‐Drug Conjugates Functionalized Engineered Exosomes in Hepatocellular Carcinoma Therapy: A Comprehensive Narrative Review
Health Science Reports · 2026-10 · 9 (10)
DOI: 10.1002/hsr2.73289 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 25.09.2026. Verfasst von Subham Sarkar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology St. Xavier's College (Autonomous) Kolkata West Bengal India. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Exosomes are naturally secreted nanovesicles with high biocompatibility, low immunogenicity, and the ability to traverse biological barriers, making them attractive theragnostic carriers. When engineered to present tumor‐specific antibodies and to deliver antibody‐drug conjugates (ADCs), they may enhance selective targeting of hepatocellular carcinoma (HCC).
Methods
This narrative review synthesizes the multidisciplinary field of exosome bioengineering, ADCs, and HCC diagnosis and therapy, covering topics from click chemistry to translational challenges. A comprehensive search of PubMed, Web of Science, and Scopus (1991–2026) identified relevant studies on exosome‐based targeted delivery, and diagnosis and therapeutics in HCC. Included studies focused on engineered exosomes, ADCs, and tumor‐specific targeting, with rigorous characterization and relevance to HCC diagnosis and therapy. The review aims to provide a conceptual synthesis, highlighting translational progress and future directions in engineered exosome‐based cancer diagnosis and therapy.
Results
The exosomal lipid bilayer protects encapsulated therapeutic cargo from premature degradation in circulation, while antibody display confers high‐affinity recognition of HCC cells. A dual‐targeting paradigm leveraging both the exosome's inherent tropism and antibody specificity supports increased intra‐tumoral delivery and reduced off‐target exposure relative to conventional modalities. Co‐loading of imaging probes can enable integrated theragnostics, facilitating visualization of biodistribution, target engagement, and treatment response. However, as clinical data remains limited, these anticipated advantages in the human therapy should be established by thorough experimentation and clinical trials.
Conclusion
ADC‐functionalized exosomes (immuno‐exosomes) can offer a suitable platform for precise HCC targeting with the potential to improve therapeutic index and enable real‐time response monitoring. Translational progress will depend on robust, scalable manufacturing, rigorous characterization of purity and potency, and comprehensive evaluation of safety, pharmacokinetics, and efficacy in preclinical models and clinical studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biotechnology St. Xavier's College (Autonomous) Kolkata West Bengal India.
- Department of Microbiology St. Xavier's College (Autonomous) Kolkata West Bengal India.
- Department of Chemistry IUBAT-International University of Business Agriculture & Technology Dhaka Bangladesh.
- Department of Microbiology Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences Chennai Tamil Nadu India.
ORCID-Profile: Subham Sarkar, Arup Kumar Mitra, Ajoy Kumer, Bikram Dhara
Zitieren
APA
Sarkar, S., Bose, A., Rajak, J., Mitra, A. K., Kumer, A., & Dhara, B. (2026). Understanding the Potential of Antibody‐Drug Conjugates Functionalized Engineered Exosomes in Hepatocellular Carcinoma Therapy: A Comprehensive Narrative Review. Health Science Reports, 9(10). https://doi.org/10.1002/hsr2.73289
Vancouver
Sarkar S, Bose A, Rajak J, Mitra AK, Kumer A, Dhara B. Understanding the Potential of Antibody‐Drug Conjugates Functionalized Engineered Exosomes in Hepatocellular Carcinoma Therapy: A Comprehensive Narrative Review. Health Science Reports. 2026;9(10). doi:10.1002/hsr2.73289
BibTeX
@article{Sarkar2026,
author = {Sarkar, Subham and Bose, Avinaba and Rajak, Jenifer and Mitra, Arup Kumar and Kumer, Ajoy and Dhara, Bikram},
title = {Understanding the Potential of Antibody‐Drug Conjugates Functionalized Engineered Exosomes in Hepatocellular Carcinoma Therapy: A Comprehensive Narrative Review},
journal = {Health Science Reports},
year = {2026},
volume = {9},
number = {10},
doi = {10.1002/hsr2.73289}
}
EUVIMED